Abstract
We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.
Original language | English (US) |
---|---|
Pages (from-to) | 1093-1097 |
Number of pages | 5 |
Journal | Leukemia Research |
Volume | 36 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2012 |
Externally published | Yes |
Keywords
- 5-Azacytidine
- Decitabine
- Leukemia
- Therapy-related cancer
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology